Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-942: mRNA-4157 + Pembrolizumab in High-Risk Melanoma
NCT03897881Phase 2Active, not recruiting
- Sponsor
- Moderna Inc
- Start
- Jul 2019
- Primary completion
- Nov 2032
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised trial of intismeran autogene in melanoma (2 arms), sponsored by Moderna Inc. Primary endpoint: Recurrence-Free Survival up to 7 years. Started Jul 2019; status: active, not recruiting.
02
Drugs
intismeran autogene
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03897881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03897881.